Arrowhead Pharmaceuticals Inc. (ARWR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Arrowhead Pharmaceuticals Inc. (ARWR) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (41% profit margin, 11% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
How ARWR Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $829.4M | 44% | 11.9% | -$1.6M | $156.9M | 10.1% |
| FY 2024 | $3.6M | 44% | -16927.1% | -$599.5M | -$604.3M | -45% |
| FY 2023 | $240.7M | 44% | -85.2% | -$205.3M | -$164.7M | -5.7% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring ARWR)
- ✓Live walkthrough of ARWR's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
ARWR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARWR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARWR. Explore sector supply chains on /butterfly.
ARWR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Arrowhead Pharmaceuticals Inc. (ARWR)?
In FY 2025 (10-K), ARWR converted $829.4M of revenue into a 44% gross margin, 11.9% operating margin, and $156.9M in free cash flow (18.9% FCF margin).